CVS Health — Feb 10, 2026 release

• Caremark ® closes out 2025 with significant customer wins and strong retention, providing momentum into 2026. 2026 Full-Year Guidance • Confirmed GAAP diluted EPS guidance range of $5.94 to $6.14 • Confirmed Adjusted EPS guidance range of $7.00 to $7.20 • Updated cash flow from operations guidance to at least $9.0 billion from at least $10.0 billion CEO Commentary “Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses. From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.”    - David Joyner, CVS Health President and CEO WOONSOCKET, RHODE ISLAND, February 10, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2025. Financial Results Summary Three Months Ended December 31, In millions, except per share amounts 2025 2024 Change Total revenues $ 105,693  $ 97,710  $ 7,983  Operating income 2,112  2,368  (256) Adjusted operating income (1) 2,597  2,728  (131) Diluted earnings per share $ 2.30  $ 1.30  $ 1.00  Adjusted EPS (2) $ 1.09  $ 1.19  $ (0.10) Fourth quarter GAAP diluted EPS of $2.30 increased from $1.30 in the prior year. Adjusted EPS of $1.09 decreased from $1.19 in the prior year, primarily due to a decline in adjusted operating income in the Health